27
Oversold
Moving averages
SMA 200$5.83-38.59%
Company profile
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
SectorHealthcare
IndustryBiotechnology
Market cap$924.31M
P/E ratioNone
EPS$-0.23
Beta0.692
Dividend yield0.00%
52-week high$8.40
52-week low$3.56
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 44
VRTX
Vertex Pharmaceuticals Inc
RSI 44
CRSP
CRISPR Therapeutics AG
RSI 39
IOVA
Iovance Biotherapeutics Inc
RSI 63
MRNA
Moderna Inc
RSI 61
VKTX
Viking Therapeutics Inc
RSI 42
SRPT
Sarepta Therapeutics Inc
RSI 53
EDIT
Editas Medicine Inc
RSI 41
NVAX
Novavax Inc
RSI 54
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 42
RSI alerts for ARDX
Get an email the moment Ardelyx Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 13 September 2026 at 8:12 AM EDT